|Chemical and physical data|
|Molar mass||143.87 kg/mol g·mol−1|
|(what is this?)|
Research and development
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis, but data was not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
- "Archived copy" (PDF). Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.CS1 maint: archived copy as title (link)
- "Living Medical eTextbook - Rheumatology - Projects In Knowledge - Rheumatoid Arthritis Edition Table of Contents - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Lmt.projectsinknowledge.com. p. 4. Retrieved 2017-06-07.
- Richardson, Brian. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Retrieved 24 January 2018.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|